Wockhardt share price

Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. The Company has approximately three research centers globally and a chain of six super-specialty hospitals across Maharashtra and Gujarat. ;

Date Name Dividend *yield Currency 2023 Wockhardt - - INR 2022 Wockhardt - - INR 2021 Wockhardt - - INR 2020 Wockhardt - - INR 2019 Wockhardt - - INR 2018 Wockhardt - - INR 2017 Wockhardt 9.22 1.39 INR 2016 Wockhardt - - INR 2015 Wockhardt 18.43 1.07 INR 2014 Wockhardt 9.22 2.19 INR 2013 Wockhardt 4.61 0.25 INR 2012 Wockhardt - - INR 2011 Wockhardt - - INR 2010 Wockhardt - - INR Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Parameter Values Market Cap (in ₹ Cr.) 2,382.37 Earning Per Share (EPS TTM) (₹) -7.40 Price To Earnings (P/E) Ratio -29.08 Book Value Per Share (₹) 113.70 Price To Books (P/B) Ratio 1.89 EBIT Margin (%) 11.04 PAT Margin (%) 2.77 ROCE (%) 8.54 PAT Growth (%) -49.93 Total Debt to Equity (D/E) Ratio 1.41 More from Parameter MAR'18 (₹ Cr.) MAR'17 (₹ Cr.) YoY %Change Balance Sheet: Share Capital 55.32 55.27 0.09% Total Non-Current Liabilities 1,257.89 1,697.40 -25.89% Total Current Liabilities 1,789.03 1,594.02 12.23% Total Liabilities 4,341.61 4,510.74 -3.75% Total Non-Current Assets 2,674.49 2,713.97 -1.45% Currents Investments 0.00 0.00 0.00% Cash and Bank 252.73 659.78 -61.69% Total Current Assets Excluding Current Investments 1,667.12 1,796.77 -7.22% Total Assets 4,341.61 4,510.74 -3.75% Profit and Loss: Gross Sales 2,477.29 2,297.52 7.82% Net Sales 2,477.29 2,297.52 7.82% PBIDT (Excl OI) 322.89 133.45 141.96% PAT 68.66 137.12 -49.93% More from

Sector Healthcare Compare with Sector peers Industry Pharmaceuticals & Drugs Compare with Industry peers Website http://www.wockhardt.com Market Cap 3,100.92 Cr. Enterprise Value(EV) 4,863.92 Cr. 2023-03 Financial Indicators • Consolidated • Standalone Earnings per share (EPS) -38.79 Trailing Twelve Months Ending 2023-03 Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-03 Industry PE 34.68 Trailing Twelve Months Ending 2023-03 Book Value / Share 232.77 Trailing Twelve Months Ending 2023-03 Price to Book Value 0.92 Calculated using Price: 215.20 Dividend Yield 0.00 Period Ending 2022-03 No. of Shares Subscribed 14.41 Cr. 144,094,573 Shares FaceValue 5 About Wockhardt Ltd. The company is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It has many research centres and several manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. It is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt. 9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 Return on Equity (%) 30.04 12.49 7.0...

If you click ' Accept all', we and • display personalised ads and content based on interest profiles • measure the effectiveness of personalised ads and content, and • develop and improve our products and services If you do not want us and our partners to use cookies and personal data for these additional purposes, click ' Reject all'. If you would like to customise your choices, click ' Manage privacy settings'. You can change your choices at any time by clicking on the 'Privacy & cookie settings' or 'Privacy dashboard' links on our sites and apps. Find out more about how we use your personal data in our

Date Name Dividend *yield Currency 2023 Wockhardt - - INR 2022 Wockhardt - - INR 2021 Wockhardt - - INR 2020 Wockhardt - - INR 2019 Wockhardt - - INR 2018 Wockhardt - - INR 2017 Wockhardt 9.22 1.39 INR 2016 Wockhardt - - INR 2015 Wockhardt 18.43 1.07 INR 2014 Wockhardt 9.22 2.19 INR 2013 Wockhardt 4.61 0.25 INR 2012 Wockhardt - - INR 2011 Wockhardt - - INR 2010 Wockhardt - - INR Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. The Company has approximately three research centers globally and a chain of six super-specialty hospitals across Maharashtra and Gujarat. ;

Sector Healthcare Compare with Sector peers Industry Pharmaceuticals & Drugs Compare with Industry peers Website http://www.wockhardt.com Market Cap 3,100.92 Cr. Enterprise Value(EV) 4,863.92 Cr. 2023-03 Financial Indicators • Consolidated • Standalone Earnings per share (EPS) -38.79 Trailing Twelve Months Ending 2023-03 Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-03 Industry PE 34.68 Trailing Twelve Months Ending 2023-03 Book Value / Share 232.77 Trailing Twelve Months Ending 2023-03 Price to Book Value 0.92 Calculated using Price: 215.20 Dividend Yield 0.00 Period Ending 2022-03 No. of Shares Subscribed 14.41 Cr. 144,094,573 Shares FaceValue 5 About Wockhardt Ltd. The company is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It has many research centres and several manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. It is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt. 9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 Return on Equity (%) 30.04 12.49 7.0...

Als u op ' Alles accepteren' klikt, gebruiken wij en • gepersonaliseerde advertenties en content weergeven op basis van interesseprofielen • de effectiviteit meten van gepersonaliseerde advertenties en content, en • onze producten en services ontwikkelen en verbeteren Als u niet wilt dat wij en onze partners cookies en persoonsgegevens voor deze aanvullende doeleinden gebruiken, klik dan op ' Alles weigeren'. Als u uw keuzes wilt aanpassen, klik dan op ' Privacyinstellingen beheren'. Je kunt je keuzes te allen tijde wijzigen door te klikken op de links 'Privacy- en cookie-instellingen' of 'Privacydashboard' op onze sites en in onze apps. Lees ons

Parameter Values Market Cap (in ₹ Cr.) 2,382.37 Earning Per Share (EPS TTM) (₹) -7.40 Price To Earnings (P/E) Ratio -29.08 Book Value Per Share (₹) 113.70 Price To Books (P/B) Ratio 1.89 EBIT Margin (%) 11.04 PAT Margin (%) 2.77 ROCE (%) 8.54 PAT Growth (%) -49.93 Total Debt to Equity (D/E) Ratio 1.41 More from Parameter MAR'18 (₹ Cr.) MAR'17 (₹ Cr.) YoY %Change Balance Sheet: Share Capital 55.32 55.27 0.09% Total Non-Current Liabilities 1,257.89 1,697.40 -25.89% Total Current Liabilities 1,789.03 1,594.02 12.23% Total Liabilities 4,341.61 4,510.74 -3.75% Total Non-Current Assets 2,674.49 2,713.97 -1.45% Currents Investments 0.00 0.00 0.00% Cash and Bank 252.73 659.78 -61.69% Total Current Assets Excluding Current Investments 1,667.12 1,796.77 -7.22% Total Assets 4,341.61 4,510.74 -3.75% Profit and Loss: Gross Sales 2,477.29 2,297.52 7.82% Net Sales 2,477.29 2,297.52 7.82% PBIDT (Excl OI) 322.89 133.45 141.96% PAT 68.66 137.12 -49.93% More from